

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **Guanze Medical Information Industry (Holding) Co., Ltd.**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code : 2427)**

### **SUPPLEMENTAL ANNOUNCEMENT TO THE ANNUAL REPORT AND THE ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023 REGARDING ADVANCES TO AN ENTITY**

Reference is made to (i) the annual report of Guanze Medical Information Industry (Holding) Co., Ltd. (the “**Company**”) for the year ended 31 December 2023 (the “**2023 Annual Report**”); and (ii) the announcement of the annual results of the Company for the year ended 31 December 2023 published on 28 March 2024 (the “**2023 Annual Results Announcement**”). Unless otherwise defined, capitalized terms herein shall have the same meanings as those set out in the 2023 Annual Report and 2023 Annual Results Announcement.

As of 31 December 2023, the Company recorded prepayments, other receivables and other assets of RMB72.8 million, out of which RMB66.9 million was classified as prepayments (the “**Prepayments under Current Assets**”), of which almost entirely represented prepayments made to suppliers of the Group for the procurement of medical imaging film products from time-to-time in the ordinary and usual course of business and negotiated on normal commercial terms. The prepayments to suppliers of the Group represent the settlement of purchase price for the medical imaging film products prior to delivery thereof to the Group, the practice of which is in line with industry norms to secure the timely delivery of requisite products with satisfactory quality.

Pursuant to Rules 13.13 and 13.15 of the Listing Rules, where the relevant advance to an entity exceeds 8% of the assets ratio defined under Rule 14.07 of the Listing Rules (the “**Assets Ratio**”), a general disclosure obligation arises for the Company. As at 31 December 2023, out of the Prepayments under Current Assets, the Group has made certain prepayments (the “**Prepayments**”) to one of the Group’s suppliers, Shanghai Jingjiu Industrial Co., Ltd.\* (上海京就實業有限公司) (“**Shanghai Jingjiu**”), with which the outstanding balance exceeded 8% under the Assets Ratio. Therefore, the Prepayments constituted an advance to an entity under Rule 13.13 of the Listing Rules and the Company is required to disclose the details thereof in accordance with Rule 13.15 of the Listing Rules.

The details of the Group's prepayment to Shanghai Jingjiu for the year ended 31 December 2023 were as follows:

<b>Nature of transaction</b>	<b>Relevant date from which disclosure obligation of the transaction commenced</b>	<b>The approximate outstanding balance of Prepayment as at the relevant date (RMB'000)</b>	<b>The approximate percentage of the Group's total assets at the relevant date</b>
Prepayments for the procurement of medical imaging film products	1 June 2023	28,441	8.68%
Prepayments for the procurement of medical imaging film products	5 December 2023	24,754	8.01%

The Prepayments are without any interest or collateral. As some of the medical imaging film products had been delivered to the Group by Shanghai Jingjiu in July 2023 and mid-January 2024 in relation to the outstanding balance of the Prepayments in June and December 2023 respectively, the relevant portions of the Prepayments were eligible for recognition as inventory thereafter, and hence the outstanding balance of the Prepayments fell below the 8% threshold of the Assets Ratio as of end of July 2023 and mid-January 2024 respectively. Since mid-January 2024 and as of the date of this announcement, the outstanding balance of the Prepayments has remained below the 8% threshold of the Assets Ratio.

To the best of the Directors' knowledge, information and belief, after making all reasonable enquiries, Shanghai Jingjiu and its ultimate beneficial owners are not connected persons of the Company and are independent of and not connected with the Directors, chief executive and substantial shareholders of the Company or any of its subsidiaries, or any of their respective associates.

### **Remedial Actions**

The Directors consider the non-compliance of the Company with the Listing Rules to be a one-off misinterpretation of Rules 13.13 and 13.15 thereof and undertake to strengthen its relevant controls and procedures to prevent similar occurrences in future.

To prevent similar occurrences of inadvertent deviations from the Listing Rules, the Company will provide a detailed guideline relating to Rules 13.13, 13.14 and 13.15 of the Listing Rules for all the Directors as well as its management team in order to strengthen and reinforce their existing knowledge relating to disclosure requirements under Rules 13.13, 13.14 and 13.15 of the Listing Rules, as well as their ability to identify potential issues at an early stage. The Company will enhance the coordination and reporting arrangements among various subsidiaries and departments of the Group, and a special task group comprising executive Directors and senior management will be established to oversee relevant transactions of the Group, and subsidiaries will be required to closely monitor the relevant transaction, including the advance to or payable balance with the suppliers, and notify the task group of potential disclosure requirement according to the Listing Rules to ensure that applicable requirements are complied with within a timely manner.

Save as disclosed above, the Company does not have any other disclosure obligations under Rules 13.13, 13.14 and 13.15 of the Listing Rules as at the date of this announcement.

By order of the Board  
**Guanze Medical Information Industry (Holding) Co., Ltd.**  
**Meng Xianzhen**  
*Chairman of the Board*

Hong Kong, 14 May 2024

*As at the date of this announcement, the Board comprises Mr. Meng Xianzhen and Mr. Guo Zhenyu as executive directors; Ms. Meng Cathy as non-executive director; and Dr. Zhao Bin, Dr. Chang Shiwang and Dr. Wong Man Hin Raymond as independent non-executive directors.*

\* *For identification purpose only*